Completed PHASE2 INTERVENTIONAL NCT00002814

Combination Chemotherapy for Patients With Brain Cancer

A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma

Sponsor: Dartmouth-Hitchcock Medical Center

Conditions Brain and Central Nervous System Tumors

Interventions filgrastim paclitaxel topotecan hydrochloride

Updated 5 times since 2017 Last updated: Oct 26, 2011 Started: Aug 31, 1996 Primary completion: Apr 30, 2001 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Brain and Central Nervous System Tumors and is currently completed. Dartmouth-Hitchcock Medical Center leads this study, which shows 5 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dartmouth-Hitchcock Medical Center

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lebanon, United States